Skip to main content
Scope Fluidics S.A. logo

Scope Fluidics S.A. — Investor Relations & Filings

Ticker · SCP ISIN · PLSCPFL00018 LEI · 259400EUNFX4E2BEHU15 WAR Professional, scientific and technical activities
Open in API
Filings indexed 510 across all filing types
Latest filing 2025-02-14 Regulatory Filings
Country PL Poland
Listing WAR SCP

About Scope Fluidics S.A.

https://scopefluidics.com/

Scope Fluidics S.A. is a biotechnology company that develops innovative medical diagnostic solutions based on microfluidic technologies. The company's business model involves incubating projects within special-purpose vehicles (SPVs) with the goal of selling them to global strategic partners. Its primary project, developed by its subsidiary Bacteromic Sp. z o.o., is the BACTEROMIC system. This automated system provides rapid, comprehensive antimicrobial susceptibility testing (AST) to address the challenge of antibiotic resistance. Previously, the company developed the PCR|ONE system for rapid molecular diagnostics through its Curiosity Diagnostics SPV, which was acquired by Bio-Rad in 2022. The company focuses on creating fast, effective, and accessible diagnostic tools to improve healthcare outcomes.

Recent filings

Filing Released Lang Actions
Realizacja pierwszego Celu Strategicznego - Content (PL)
Regulatory Filings Classification · 1% confidence The document text is a corporate announcement from Scope Fluidics S.A. written in Polish. It details the achievement of a strategic goal related to establishing special purpose vehicles (spółek celowych) for new projects (Hybolic and EDOCERA). This content relates to the company's strategic development, project pipeline, and corporate structure changes concerning new ventures. It is not a full annual report (10-K), an earnings release (ER), a dividend notice (DIV), or a director's dealing report (DIRS). Since it discusses strategic progress and the formation of new entities related to business development, it best fits under general corporate updates. Given the options, it is a specific business/strategy update that doesn't perfectly align with the highly specific categories like M&A (TAR) or Financing (CAP). However, since it is a formal report detailing strategic progress and corporate structure changes related to new projects, it falls under general corporate reporting. As it is a specific update on strategic execution rather than a standard financial report, and it doesn't fit the other specific categories, the most appropriate general classification is Regulatory Filings (RNS), which serves as a fallback for specific corporate announcements not covered elsewhere, or potentially Management Reports (MDA) if it were a more detailed explanation of results, but RNS is safer for non-standard, mandatory disclosures. Revisiting the definitions: This is a 'raport bieżący' (current report) announcing the fulfillment of a strategic milestone involving the creation of new subsidiary companies for specific projects. This type of strategic operational update is often classified under general regulatory filings if a more specific category like 'M&A' or 'Capital Change' is not applicable. Since it is a specific, non-financial performance announcement, RNS (Regulatory Filings) is the most suitable general category.
2025-02-14 Polish
Realizacja pierwszego Celu Strategicznego
Capital/Financing Update Classification · 1% confidence The document is a corporate announcement written in Polish by 'Scope Fluidics S.A.' It details the achievement of a strategic goal related to establishing new projects as special purpose vehicles (spółek celowych). It references previous reports (raportem bieżącym nr 09/2023, nr 22/2024, nr 08/2024) regarding strategy and project registration (Hybolic, EDOCERA). This type of announcement, reporting on strategic progress, project development, and corporate structure changes (establishing new entities), does not fit neatly into the specific financial reporting categories (10-K, IR, ER) or specific event categories (DIV, DIRS, AGM-R). Since it is a general, ongoing update about corporate strategy and development that doesn't match a more specific code, the most appropriate fallback category is Regulatory Filings (RNS), which covers general regulatory announcements.
2025-02-14 Polish
Harmonogram publikacji raportów okresowych w 2025 roku - Content (PL)
Report Publication Announcement Classification · 1% confidence The document text explicitly outlines the planned schedule for the company's periodic reports (annual, Q1, H1, Q3) for the year 2025, citing specific Polish regulatory paragraphs ('§ 62 ust. 1', '§ 79 ust. 2') and the legal basis ('Art. 56 ust. 1 pkt 2 Ustawy o ofercie'). This is not the report itself, but an announcement detailing *when* future reports will be published. This fits the definition of a Report Publication Announcement (RPA), which covers announcements regarding the timing or release of company reports. The document length is short (1177 chars), further supporting the RPA classification over the full report classification (like 10-K or IR).
2025-01-24 Polish
Podsumowanie wyników Early Access Program - Content (PL)
Regulatory Filings Classification · 1% confidence The document is a follow-up report (Raport bieżący nr 5/2024) summarizing the results of an Early Access Program (EAP) for the BACTEROMIC system, comparing its performance (Essential Agreement and Category Agreement) against a leading competitive system in microbiological labs. It details technical performance metrics (MIC measurements) and discusses the system's maturity for commercial launch and potential M&A implications. This content—a detailed update on product testing, performance validation, and strategic outlook following initial development—is characteristic of an Investor Presentation (IP) or a Management Discussion & Analysis (MDA) section, but given the focus on technical validation results and strategic positioning for investors/acquirers, 'Investor Presentation' (IP) is the most fitting category for this type of detailed, non-statutory performance summary. It is not a standard regulatory filing (10-K, IR, ER) but rather a strategic communication to the market about product validation.
2025-01-08 Polish
Wyniki pierwszej fazy prac nad oprogramowaniem do "fast detection" - Content (PL)
Regulatory Filings Classification · 1% confidence The document is a formal announcement from the Management Board ("Zarząd") of Scope Fluidics S.A. regarding the successful completion and positive assessment of the 'Proof of Concept' (PoC) phase for new diagnostic software (an interpreter for 'fast detection' of bacterial growth and antibiotic susceptibility). It details technical results (Essential Agreement levels, timeframes for different bacterial groups like Pseudomonas), and outlines future R&D steps (developing 'Panel Rapid BSI' and 'Panel Rapid UNI'). This content describes internal operational progress, technical validation, and future strategy related to product development, which is characteristic of a general business update or management report, rather than a formal financial filing (like 10-K, ER, or IR). Since it is a detailed update on business progress and technical validation provided by management, it best fits the Management Reports (MDA) category, which covers management's explanation of business trends and outlook, even if the focus here is technical validation.
2025-01-08 Polish
Skonsolidowany raport GK Scope Fluidics SA za III kwartał 2024 r.
Interim / Quarterly Report Classification · 1% confidence The document is a quarterly report ('Raport kwartalny') for Scope Fluidics S.A. covering the nine-month period ending September 30, 2024. It contains comprehensive financial statements, including consolidated and standalone statements of profit or loss, financial position, and cash flows, as well as detailed explanatory notes. This fits the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-11-29 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.